- Primary endpoint met in both trials
- Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate
- Chronic hepatitis B (CHB) accounts for… [+6751 chars]
GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B - GSK
Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate
Source:Gsk.com
Published:
Related News
Dow jumps 400 points as stocks rebound for a second day after Trump calls off Greenland-related tariffs: Live updates - CNBC
Major U.S. stock averages immediately jumped after President Donald Trump said he would no longer impose his new Europe tariffs that were set to begin Feb. 1.
CNBC•Sean Conlon, Pia Singh
Monster Winter Storm Expected To Snarl Air Travel This Weekend - Forbes
A whopper snowstorm is expected to bring “life-threatening cold air” and dangerous travel conditions across a large swath of the United States this weekend.
Forbes•Suzanne Rowan Kelleher
Jobless claims point to a more stable labor market - MarketWatch
MarketWatch•Greg Robb